(Q40931458)

25 September 2017

title

Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein (English)

1 reference

25 September 2017

1 reference

Le Buanec H

1

1 reference

25 September 2017

Lachgar A

2

1 reference

25 September 2017

D'Anna R

3

1 reference

25 September 2017

Zagury JF

4

1 reference

25 September 2017

Bizzini B

5

1 reference

25 September 2017

Bernard J

6

1 reference

25 September 2017

Ittelé D

7

1 reference

25 September 2017

Hallez S

8

1 reference

25 September 2017

Giannouli C

9

1 reference

25 September 2017

Burny A

10

1 reference

25 September 2017

Zagury D

11

1 reference

25 September 2017

publication date

1 August 1999

1 reference

Biomedicine and Pharmacotherapy

25 September 2017

published in

1 reference

25 September 2017

volume

53

1 reference

25 September 2017

issue

7

1 reference

25 September 2017

page(s)

323-328

1 reference

Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

A dot-immunobinding assay for monoclonal and other antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

Convenient assay for interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988505-4

7 January 2021

10.1016/S0753-3322(00)88505-4

Identifiers

DOI

1 reference

25 September 2017

1 reference